3rd Quarter - Report
RARE DISEASE COMPANY COALITION for RARE DISEASE COMPANY COALITION
Income
—
Expenses
$90,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
HR 1 - Big Beautiful Bill Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| YOKO ROSENBAUM | — |
Pharmacy PHA
HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals
| Lobbyist | Covered position, as disclosed |
|---|---|
| STACEY FRISK | — |
| YOKO ROSENBAUM | — |
Trade (domestic/foreign) TRD
Sec. 232 Pharmaceutical Tariffs
| Lobbyist | Covered position, as disclosed |
|---|---|
| YOKO ROSENBAUM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.